N-Acetylcysteine Amide not checked
Nacuity Pharmaceuticals, Inc. · NPI-001
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “N-acetylcysteine amide (NPI-001) tablets (250 mg), taken BID”In the company’s words, NCT07290530 on ClinicalTrials.gov
- Tested for
- Retinitis Pigmentosa (RP) (2 trials), Usher Syndrome (2 trials)
- Main trialPhase 3
- “The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001. The main questions it aims to answer are: Does NPI-001 slow down the loss of photoreceptors? What medical problems do participants have when taking NPI-001? Researchers will compare NPI-001 to a placebo (a look-alike substance that contains no drug) to see if NPI-001 works to preserve vision. Participants will: Take NPI-001 or a placebo twice a day, every day for 24 months and visit…”In the company’s words, NCT07710196 on ClinicalTrials.gov
- Other names
- NPI-001
Other drugs for Retinitis Pigmentosa (RP)
- UltevursenLaboratoires Thea · Phase 2
- OpCT-001BlueRock Therapeutics · Phase 1/2
- AAVB-081AAVantgarde Bio Srl · Phase 1/2
Coming up2
- Apr 2029Phase 3 trial completes · ClinicalTrials.gov
- Jul 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Apr 2029 | A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome | |
| Phase 3Not yet recruiting | Jul 2029 | 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome | |
| Phase 1/2Completed | 20 Jun 2025 | Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome | |
| Phase 1/2Completed | 26 May 2026 | PK and PD Study of NPI-001 and Cysteamine Bitartrate |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026